KV Pharmaceutical, Purdue Pharma settle painkiller patent dispute - Nashville Business Journal:

http://headsup.org/campuses/emschool.html
Under the settlement, KV agreed to no longed disputethe “validity, enforceabilithy or infringement” of the Purdue generic oxycodone patents. In Purdue granted KV a limited, non-exclusivre license to manufactureand sell, in the Unitedd States, a certain amount of various dosagr strengths of the drugs as long as KV pays royaltieas to Purdue. KV also reached a deal to be an authorized, non-exclusivr distributor in the United States of certain generic versiondsof OxyContin. These agreements settle three paten infringementlawsuits Stamford, Conn.-based Purdue filedf against KV in 2007. KV still facee more lawsuits fromother companies, consumerse and shareholders.
Three individuals in St. Claire County Circuit Court against KV, allegingf that certain drugs containedf a potentially lethal amount of morphin due to oversized tablets that were eventuallyt recalled by thepharmaceutical company. Last , a Florida-based dermatology sued KV, of a patenty for Duac topical gel, an acne KV also faces lawsuits from shareholders abourt manufacturing compliance andthe company’s financial prospects. Mo.-based KV has and recalled painkillers.
In KV said it with the FDA that outlines a serie s of measures that will permitg KV and its subsidiaries to resume manufacturingand